patients presenting with varicella symptoms may result in misdiagnosis and/or mistreatment. This study investigated the diagnostic and treatment strategies used by HCPs for managing varicella infections in US children.

Methods. An online cross-sectional survey of licensed HCPs was conducted, after an Institution review board approval and HCP consent. Eight clinical vignettes with information on patients with varying varicella symptoms (representing uncomplicated and complicated cases) were presented. For each vignette, HCPs selected a diagnosis and appropriate intervention(s) from pre-determined lists. Descriptive analyses were performed.

Results. A total of 153 HCPs (50 nurses, 103 doctors) completed the survey. Mean age was 44 years, 62% were female, and 82% were licensed after 1995. Varicella infection was correctly diagnosed 79% of the time. HCPs were able to recognize uncomplicated cases of varicella 85% of the time and complicated cases 61% of the time. HCPs recommended the correct intervention 43% of the time for uncomplicated cases and 25% of the time for complicated cases. For example, HCPs recommended antibiotics 17% of the time and/or antivirals 18% of the time (Table 1), of which 25% and 69% (respectively) were not appropriate per the American Academy of Pediatrics guidelines respectively. Antibiotics were incorrectly recommended 6% of the time for uncomplicated cases of varicella.

Conclusion: Given the low incidence of varicella infections in the US, complicated cases of varicella may be under-recognized or inappropriately treated by some HCPs. Additional training may help HCPs better recognize/ treat cases of varicella. Further, ensuring high rates of varicella vaccination is important to avoid vaccine preventable conditions and to minimize unnecessary exposure to antimicrobial and antiviral therapies.

Disclosures. Jaime Fergie, MD, AstraZeneca (Speaker's Bureau) Sobi, Inc. (Speaker's Bureau) Manjiri D. Pawaskar, PhD, Merck & Co., Inc (Employee, Shareholder) Phani Veerkani, MD, DrPH, Merck (Research Grant or Support) Salomon Chen, MBBS, MPH, Merck, NJ, USA (Employee, Shareholder) Carolyn Harley, PhD, Merck (Consultant) Joanna MacEwan, PhD, PRECISIONheal (Employee) Taylor T. Schwartz, MPH, Merck (Consultant, Grant/ Research Support, Scientific Research Study Investigator, Research Grant or Support) Shikha Surati, MPH, Merck & Co., Inc. (Employee, Shareholder)

1388. DTaP-containing combination vaccines use and adherence to the recommended infant-toddler vaccination series among privately insured children in the US
Matthew M. Loiacono, MSc; Vitali Pool, MD; Robertus Van Aalst, MSc; Sanofi Pasteur, Nazareth, Pennsylvania

Session: P-63. Pediatric Vaccines

Background. Despite universal recommendation of the 3 + 1 diphtheria, tetanus, and pertussis (DTaP) vaccine series in infants and toddlers, adherence (i.e. coverage and timeliness) remains suboptimal in the US. Complicating vaccine uptake, increasingly, interventions are recommended to improve vaccine coverage rates and timeline, but research on this topic is limited. The purpose of this study was to compare adherence to the recommended infant-toddler vaccination series between recipients of DTaP-containing combination vaccines (i.e. quadrivalent/pentavalent) and stand-alone vaccines (i.e. trivalent).

Methods. We used the Optum de-identified Clinformatics Data Mart database to create a cohort of children born between 2009 and 2016 with > 24 months of continuous enrollment from birth, and records of ≥ 1 DTaP vaccine receipt. Patients were classified by DTaP-containing vaccine receipt: combination vaccines only, stand-alone vaccines only, or a mixture of both. The primary adherence outcome was completion of the 4-dose series within 20 months of life. We adjusted outcomes for gender, birth year, race, and socioeconomic status via a logistic regression model.

Results. The cohort contained 200,568 female (48.6%) and 211,882 male (51.4%) children. Of these children, 167,091 received combination vaccines only (40.5%), 61,342 received stand-alone vaccines only (14.9%), and 184,017 received a mixture of both (44.6%). Completion of the 4-dose series was highest among children who received combination vaccines only (75.5%), followed by those who received a mixture of vaccines (72.7%) and those who received stand-alone vaccines only (54.5%). Relative to those who received stand-alone vaccines only, adjusted odds of completing the series were approximately 2.9 times higher among combination vaccine recipients (odds ratio, OR = 2.93 [95% CI: 2.87, 2.98]) and 2.5 times higher among those who received a mixture of vaccines (OR = 2.54 [2.49, 2.59]).

Conclusion: Use of DTaP-containing combination vaccine use was associated with significantly greater adherence. Although these results warrant further investigation to better understand the determinants of infant vaccination adherence, such evidence may further support preferential recommendations for combination vaccine use.

Disclosures. Matthew M. Loiacono, MSc; Sanofi Pasteur (Employee) Vitali Pool, MD, Sanofi Pasteur (Employee) Robertus Van Aalst, MSc, Sanofi Pasteur (Employee)

1389. Economic Evaluation of Universal Varicella Vaccination in Mexico
Enrique Chacon-Cruz, MD, Polyclinic; Estelle Meroc, DVM, MPH, PhD; Sue Ann Costa-Clemens, MD, PhD, Thomas Verstraeten, MD, MPH, MSc; University of Siena, Italy; Tijuana, Baja California, Mexico; Pfizer Vaccinology and Epidemiology Services, Leuven, Belgium, Leuven, Vlaams-Brabant, Belgium

Session: P-63. Pediatric Vaccines

Background. Universal varicella vaccination (UVV) has proven to be cost-effective in countries where implemented. However, this has not yet been evaluated for Mexico. We assessed the cost-effectiveness of UVV in the Mexican immunization Program from both healthcare and societal perspectives.

Methods. The annual disease burden (varicella cases/deaths, outpatient visits, hospitalizations) were derived from Mexican seroprevalence-published data adjusted to the 2020 country’s population. The annual economic burden was calculated by combining disease with Mexican published unit cost data. Four different vaccination strategies were evaluated: 1. One dose of a single varicella vaccine at 1 year old; 2. Two doses of single varicella vaccine at 1 and 6 years; 3. One dose of a single varicella vaccine at 1 year, and quadrivalent measles-mumps-rubella-varicella vaccine (MMRV) at 6 years; 4. Two doses of MMRV at 1 and 6 years.

We developed an economic model for each vaccination strategy where 20 consecutive birth cohorts were simulated. The impact of vaccination (number of avoided cases/ deaths) was evaluated for a 20 years follow-up period based on vaccine effectiveness (87% and 97.4%), and assuming a 95% coverage. Subsequently, we estimated net vaccination costs, benefit-cost ratio (BCR), annual costs saved, cost-effectiveness ratio.

Results. From annual disease burden estimation, avoided cases with one dose, and two doses were of 20,570,722 and 23,029,751 respectively. From the 20 years cohort, the yearly number of varicella cases was estimated at 2,041,296, and total costs at $115,565,315 (US$) (healthcare perspective) and $165,372,061 (healthcare and societal perspectives). Strategies 1 and 2 were found to be cost-saving (BCR > 1) (Figure 1), and strategy 3 to be cost-effective (CE) ($1539 per Life Year Gained). Strategy 4 was not CE. Strategies 1 and 2 would allow saving annually up to $52.16 million and $34.41 million, respectively, to the Mexican society.

FIGURE 1

Conclusion. 1. The disease and economic burden of varicella in Mexico are high. 2. UVV with four different vaccination strategies results in a high reduction of cases. 3. From healthcare and societal perspectives, UVV was shown to be cost-effective (with strategy 3), and cost-saving (with strategies using one dose or two doses separately).

Disclosures. All Authors: No reported disclosures

1390. Effectiveness of M-M-R-II in outbreaks - a systematic literature review of real-world observational studies
Se Li, PhD1; Barbara J. Kuter, PhD, MPH; Elvira Schmidt, MSc2; Elizabeth Richardson, BS3; Louise P. Salulhti, PhD4; Neumann Monika, Information Specialist1; Linnea Koller, n/a1; Manica Agrawal, n/a1; Manjiri D. Pawaskar, PhD5; Merck & Co., Inc.6; Kenilworth, New Jersey; Prime Vaccine Consulting, Collegeville, Pennsylvania; Certara Germany GmbH, Loerrach, Baden-Wurttemberg, Germany; Merck Sharp & Dohme Corp., North Wales, Pennsylvania; Merck & CO. Inc., Plymouth Meeting, Pennsylvania

Session: P-63. Pediatric Vaccines

Background. M-M-R-II was approved in the US in 1978 and has been used globally for over 40 years. Widespread use of M-M-R-II has resulted in important declines in incidence, morbidity, and mortality of measles, mumps, and rubella in the US and other countries. While vaccine immunogenicity and efficacy were established in multiple placebo-controlled trials of each vaccine component, there are limited studies on vaccine effectiveness (VE) of M-M-R-II. This systematic literature review was conducted to summarize the VE of M-M-R-II from real-world observational studies.

Methods. The literature search was conducted in Medline and Embase (through May 2019), and grey literature sources (through July 2019). All publications and findings in English language were screened by two independent reviewers. The study characteristics and VE results were extracted for each study.